Institution
Myriad Genetics
Company•Munich, Germany•
About: Myriad Genetics is a company organization based out in Munich, Germany. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 562 authors who have published 586 publications receiving 56046 citations. The organization is also known as: Myriad Genetics, Inc..
Topics: Cancer, Breast cancer, Gene, Population, Prostate cancer
Papers published on a yearly basis
Papers
More filters
•
30 Sep 2011TL;DR: In this article, a molecular classification of disease and particularly methods and compositions for determining BRCA deficiency were described, and the invention generally relates to a molecular classi cation of disease.
Abstract: The invention generally relates to a molecular classification of disease and particularly to methods and compositions for determining BRCA deficiency.
4 citations
••
TL;DR: Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most commonly mutated proto-oncogene identified in cancer and still remains an arduous therapeutic challenge.
Abstract: 3547Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most commonly mutated proto-oncogene identified in cancer and still remains an arduous therapeutic challenge. Recently, KRAS...
4 citations
••
TL;DR: A high tumor BRCA1/2 dysfunction rate in HGSC with a unique predominance of BRC a2 over BRCa1 mutations is observed, and no survival differences were observed between B RCA1-methylated and BRCS/2 wild-type non-BRCA 1- methylated cancers.
Abstract: Objective The therapeutic benefits of poly(ADP-ribose) polymerase inhibitors highlight the need to evaluate BRCA1/2 defects in tubal/ovarian cancer (OC). We sought to determine the pattern and disease characteristics associated with tumor BRCA1/2 mutations and BRCA1 methylation in women with OC. Methods We obtained 111 OC specimens from 2 university hospitals and assessed BRCA1/2 mutations and BRCA1 methylation in tumor DNA. The frequency and pattern of BRCA1/2 defects were examined. Associations between patient/disease characteristics and BRCA1/2 defects were ascertained (Fisher's exact test). Platinum-free interval (PFI), progression-free survival (PFS), and overall survival (OS) based on the underlying BRCA1/2 defect were determined (Kaplan-Meier analysis [log-rank test]). Results We observed a BRCA1/2 dysfunction rate of 40% (28/70) in high-grade serous tubal/ovarian cancer (HGSC), including 14.3% BRCA1 methylation (n=10), 7.1% BRCA1 mutation (n=5), and 18.6% BRCA2 mutation (n=13). Defects in BRCA1/2 genes were associated with stage III/IV HGSC (BRCA1 methylation: P=0.005 [stage III/IV] and P=0.004 [HGSC]; BRCA1/2 mutation: P=0.03 [stage III/IV] and P<0.001 [HGSC]). Patients with BRCA1/2-mutated cancers showed improved OS (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43-0.99; P=0.045) and a trend toward improved PFI (HR, 0.48; 95% CI, 0.22-1.06; P=0.07) and PFS (HR, 0.72; 95% CI, 0.51-1.03; P=0.07). No survival differences were observed between BRCA1-methylated and BRCA1/2 wild-type non-BRCA1-methylated cancers. Conclusion We observed a high tumor BRCA1/2 dysfunction rate in HGSC with a unique predominance of BRCA2 over BRCA1 mutations. While BRCA1/2 mutations conferred survival benefits in OC, no such association was observed with BRCA1 methylation.
4 citations
••
TL;DR: It is submitted that several methodological weaknesses compromise the validity of the study’s results and conclusions, including use of a suboptimal reference standard and adoption of an alternative, author-devised classification system that is not consistent with the clinically-validated classification system provided with the myPath test results.
4 citations
Authors
Showing all 562 results
Name | H-index | Papers | Citations |
---|---|---|---|
Richard D. Smith | 140 | 1180 | 79758 |
Rosalind A. Eeles | 106 | 544 | 45058 |
David E. Goldgar | 103 | 419 | 50450 |
Mark H. Pollack | 89 | 464 | 26511 |
Jacques Simard | 83 | 409 | 28493 |
Julian R. Sampson | 71 | 212 | 22192 |
Johanna M. Rommens | 71 | 202 | 42630 |
David A. Frank | 68 | 201 | 17557 |
Sean V. Tavtigian | 65 | 194 | 35641 |
Mark H. Skolnick | 64 | 211 | 30548 |
Lisa A. Cannon-Albright | 62 | 327 | 28945 |
Alexander Gutin | 54 | 167 | 17705 |
Dominic P. Williams | 49 | 134 | 6665 |
Nelleke A. Gruis | 49 | 159 | 13080 |
Nicola J. Camp | 46 | 213 | 7772 |